| pubmed-article:18668307 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18668307 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18668307 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:18668307 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:18668307 | lifeskim:mentions | umls-concept:C1709527 | lld:lifeskim |
| pubmed-article:18668307 | lifeskim:mentions | umls-concept:C1533699 | lld:lifeskim |
| pubmed-article:18668307 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:18668307 | lifeskim:mentions | umls-concept:C1439292 | lld:lifeskim |
| pubmed-article:18668307 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:18668307 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:18668307 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:18668307 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:18668307 | pubmed:dateCreated | 2008-9-9 | lld:pubmed |
| pubmed-article:18668307 | pubmed:abstractText | Gemtuzumab Ozogamicin (GO) is a humanized anti-CD33 antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin-g1. It was developed at the end of the nineties as 90% of the leukemic blast population of patients with acute myeloid leukaemia (AML) express the CD33 surface antigen (Dinndorf et al. [1] Blood 1986;67:1048-53). GO is currently approved in monotherapy for the treatment of CD33+ AML patients in first relapse, showing a 26% overall response rate and a median disease-free-survival of 5.2 months for responders (Larson et al. [2] Cancer 2005;104:1442-52). CD33 antigen expression is also observed at diagnosis (in 15% of cases) (Pui et al. [3] J Clin Oncol 1998;16:3768-73) or at relapse (Guglielmi et al. [4] Leukemia 1997; 11:1501-7) of acute lymphoblastic leukaemia (ALL), representing a potential cellular target for ALL patients. Case series have already demonstrated the efficacy of GO in children with relapsed CD33+ ALL with documentation of complete remission (CR) (Balduzzi et al. [5] Leukemia 2003;17:2247-8; Cotter et al. [6] Br J Haematol 2003;122:686-91; Zwaan et al. [7] Leukemia 2003;17:468-70). In the other hand, there is no report at our knowledge of the use of GO in the setting of adult CD33+ ALL patient. Here we report the case of a 30-year-old man with a refractory CD33+ ALL who received a salvage regimen combining chemotherapy + GO and achieved a transient CR. | lld:pubmed |
| pubmed-article:18668307 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18668307 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18668307 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18668307 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18668307 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18668307 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18668307 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18668307 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18668307 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18668307 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18668307 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18668307 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18668307 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:18668307 | pubmed:issn | 0925-5710 | lld:pubmed |
| pubmed-article:18668307 | pubmed:author | pubmed-author:HarousseauJea... | lld:pubmed |
| pubmed-article:18668307 | pubmed:author | pubmed-author:ChevallierPat... | lld:pubmed |
| pubmed-article:18668307 | pubmed:author | pubmed-author:GarandRichard... | lld:pubmed |
| pubmed-article:18668307 | pubmed:author | pubmed-author:TalmantPascal... | lld:pubmed |
| pubmed-article:18668307 | pubmed:author | pubmed-author:DelaunayJacqu... | lld:pubmed |
| pubmed-article:18668307 | pubmed:author | pubmed-author:MaheBeatriceB | lld:pubmed |
| pubmed-article:18668307 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18668307 | pubmed:volume | 88 | lld:pubmed |
| pubmed-article:18668307 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18668307 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18668307 | pubmed:pagination | 209-11 | lld:pubmed |
| pubmed-article:18668307 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:meshHeading | pubmed-meshheading:18668307... | lld:pubmed |
| pubmed-article:18668307 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18668307 | pubmed:articleTitle | Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression. | lld:pubmed |
| pubmed-article:18668307 | pubmed:affiliation | Department of Hematology, Centre Hospitalier Universitaire, Nantes, France. patrice.chevallier@chu-nantes.fr | lld:pubmed |
| pubmed-article:18668307 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18668307 | pubmed:publicationType | Case Reports | lld:pubmed |
